Fen-Yu Tseng1, Szu-Tah Chen2, Jung-Fu Chen3, Tien-Shang Huang1, Jen-Der Lin2, Pei-Wen Wang3, Wayne Huey-Herng Sheu4, Tien-Chun Chang5. 1. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Internal Medicine, Linkuo Chang Gung Memorial Hospital, Taoyuan, Taiwan. 3. Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 4. Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. 5. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: tienchunchang@ntu.edu.tw.
Abstract
BACKGROUND/ PURPOSE: The objectives of this study were to evaluate the associations between clinical parameters and quality of life (QOL) of patients with acromegaly in Taiwan and to identify the impacts of hormone control, regimens, or co-morbidities on acromegalic patients' daily life. METHODS: From 2013 to 2015, subjects with acromegaly were recruited through five medical centers. Clinical data were recorded. The QOL of enrolled patients were assessed by using Acromegaly Quality of Life Questionnaire (AcroQoL). RESULTS: This study enrolled 272 acromegalic subjects (117 males, 155 females). Remission, defined by normalization of IGF-1, had significant positive association with QOL scores in psychological/appearance (PSY/APP) dimension (β = 6.760, p = 0.023). Somatostatin analogues therapy had negative associations with total score and score in psychological (PSY) dimension (β = -4.720, p = 0.046 and β = -5.388, p = 0.035, respectively). Diabetes mellitus had negative associations with score in PSY dimension and psychological/personal relations (PSY/PER) dimensions (β = -5.839, p = 0.034 and β = -7.516, p = 0.013, respectively). Cerebral vascular accident (CVA) had significant negative associations with total score and scores in physical (PHY), PSY, and PSY/PER dimensions (β = -26.632, p = 0.013; β = -28.353, p = 0.024; β = -25.648, p = 0.026; and β = -34.586, p = 0.006, respectively). All these associations remained significant even after adjusted with sex and age. CONCLUSION: Our analysis suggested that not only hormone control but also therapeutic regimens and presence of co-morbidities might affect QOL of patients with acromegaly in some dimensions.
BACKGROUND/ PURPOSE: The objectives of this study were to evaluate the associations between clinical parameters and quality of life (QOL) of patients with acromegaly in Taiwan and to identify the impacts of hormone control, regimens, or co-morbidities on acromegalicpatients' daily life. METHODS: From 2013 to 2015, subjects with acromegaly were recruited through five medical centers. Clinical data were recorded. The QOL of enrolled patients were assessed by using Acromegaly Quality of Life Questionnaire (AcroQoL). RESULTS: This study enrolled 272 acromegalic subjects (117 males, 155 females). Remission, defined by normalization of IGF-1, had significant positive association with QOL scores in psychological/appearance (PSY/APP) dimension (β = 6.760, p = 0.023). Somatostatin analogues therapy had negative associations with total score and score in psychological (PSY) dimension (β = -4.720, p = 0.046 and β = -5.388, p = 0.035, respectively). Diabetes mellitus had negative associations with score in PSY dimension and psychological/personal relations (PSY/PER) dimensions (β = -5.839, p = 0.034 and β = -7.516, p = 0.013, respectively). Cerebral vascular accident (CVA) had significant negative associations with total score and scores in physical (PHY), PSY, and PSY/PER dimensions (β = -26.632, p = 0.013; β = -28.353, p = 0.024; β = -25.648, p = 0.026; and β = -34.586, p = 0.006, respectively). All these associations remained significant even after adjusted with sex and age. CONCLUSION: Our analysis suggested that not only hormone control but also therapeutic regimens and presence of co-morbidities might affect QOL of patients with acromegaly in some dimensions.
Authors: Małgorzata Rolla; Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Marcin Kałużny; Bogumil M Konopka; Izabela Błoniecka; Grzegorz Zieliński; Marek Bolanowski Journal: Front Endocrinol (Lausanne) Date: 2021-03-16 Impact factor: 5.555